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Summary. Principal stratification is a causal framework to analyze randomized experiments with a
post-treatment variable between the treatment and endpoint variables. Because the principal strata
defined by the potential outcomes of the post-treatment variable are not observable, we generally can-
not identify the causal effects within principal strata. Motivated by a real data set of phase III adjuvant
colon clinical trials, we propose approaches to identifying and estimating the principal causal effects via
multiple trials. For the identifiability, we remove the commonly-used exclusion restriction assumption by
stipulating that the principal causal effects are homogeneous across these trials. To remove another
commonly-used monotonicity assumption, we give a necessary condition for the local identifiability,
which requires at least three trials. Applying our approaches to the data from adjuvant colon clinical
trials, we find that the commonly-used monotonicity assumption is untenable, and disease-free survival
with three-year follow-up is a valid surrogate endpoint for overall survival with five-year follow-up, which
satisfies both the causal necessity and the causal sufficiency. We also propose a sensitivity analysis
approach based on Bayesian hierarchical models to investigate the impact of the deviation from the
homogeneity assumption.
Keywords: Causal inference; Causal necessity; Causal sufficiency; Clinical trial; Criterion for
surrogate endpoints
1. Introduction
1.1. Principal stratification and surrogate endpoints
Causal effects are defined as comparisons between potential outcomes of the endpoint variable
under treatment and control for the same group of individuals. To evaluate the causal effects on the
endpoint within subpopulations stratified by a post-treatment variable, Frangakis and Rubin (2002)
proposed the principal stratification framework in which the subpopulations are defined by the joint
values of the potential outcomes instead of the observed value of the post-treatment variable. The
joint potential outcomes of the post-treatment variable can be viewed as a pretreatment covariate
vector unaffected by the treatment. Principal stratification has several applications in the current
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literature. The compliance behavior defined by the potential treatment acceptances is used to
address the noncompliance problem (Angrist et al., 1996), the potential survival status is used to
evaluate the effect on the quality of life with truncation by death (Rubin, 2006; Ding et al., 2011;
Yang and Small, 2015), and the potential employment status is used to deal with the truncation of
wages due to unemployment in the evaluation of job-training programs (Zhang and Rubin, 2003;
Zhang et al., 2009; Frumento et al., 2012). The potential response indicators are used to address
non-ignorable nonresponse problems (Frangakis and Rubin, 1999; Mealli and Pacini, 2008; Mattei
et al., 2014), and the potential intermediate variables are used to define direct and indirect effects
(Rubin, 2004; Gallop et al., 2009; Mattei and Mealli, 2011).
Another important application of principal stratification is to evaluate surrogate endpoints in
clinical trials (Frangakis and Rubin, 2002). When direct measurement of an endpoint of interest
is too time-consuming or costly, we try to measure a surrogate for the endpoint. There have been
some criteria for judging surrogates from different points of view. Prentice (1989) first proposed the
statistical surrogate criterion, which requires conditional independence of the treatment and the
observed endpoint given the observed surrogate. From a causal perspective, Frangakis and Rubin
(2002) proposed the principal surrogate criterion, and pointed out that the statistical surrogate does
not satisfy the causal necessity, i.e., no difference between the potential outcomes of the surrogate
implies no difference between the potential outcomes of the endpoint. Lauritzen (2004) proposed
the strong surrogate criterion depicted by a causal diagram requiring the surrogate break the causal
path from the treatment to the endpoint, which is stronger than the principal surrogate. Gilbert and
Hudgens (2008) argued that a principal surrogate should satisfy not only causal necessity but also
causal sufficiency. The causal sufficiency requires that if the treatment effect on the surrogate is non-
zero, then the treatment effect on the endpoint is also non-zero. Joffe and Greene (2009) considered
four different approaches for evaluating surrogate endpoints. However, all of these approaches may
suffer from the surrogate paradox as pointed out by Chen et al. (2007), Ju and Geng (2010) and
VanderWeele (2013). That is, for a surrogate satisfying any of these criteria, it is possible that the
treatment has a negative average causal effect on the endpoint even if the treatment has a positive
average causal effect on the surrogate and the surrogate has a positive average causal effect on the
endpoint.
For evaluating surrogates, Mealli and Mattei (2012) suggested conducting a principal stratifica-
tion analysis investigating the effect of the treatment within all principal strata. However, because
we cannot simultaneously observe two potential outcomes of the post-treatment variable, we do
not know the principal stratum of an individual, and generally we cannot identify causal effects
within principal strata. Zhang and Rubin (2003) and Cheng and Small (2006) proposed large sam-
ple bounds of causal effects within some principal strata, which, however, may be too wide to be
informative. Angrist et al. (1996) discussed the identifiability of the complier average causal effect
under the monotonicity and exclusion restriction assumptions. Without the exclusion restriction
assumption, Zhang et al. (2009) used Gaussian mixture models to identify causal effects within
principal strata. Gilbert and Hudgens (2008) and Huang and Gilbert (2011) proposed approaches
to evaluating surrogates based on principal stratification in a single trial, but they assumed constant
potential outcomes of the surrogate under control. Zigler and Belin (2012) proposed a Bayesian
approach to estimating the causal effects on the endpoint within principal strata without the mono-
tonicity assumption, but their approach relied on prior distributions on some parameters that are
not identifiable.
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1.2. Motivation
Our study is motivated by the data from phase III adjuvant colon clinical trials (ACCTs). The
goal of the ACCTs is to test whether disease-free survival (DFS) with three-year follow-up can be
used as a surrogate for the overall survival (OS) with five-year follow-up (Sargent et al., 2005). The
data are collected from 10 clinical trials. Sargent et al. (2005) found a strong correlation between
the hazard ratio of the treatment on DFS and the hazard ratio of the treatment on OS. Applying a
meta-analysis, Baker et al. (2012) used DFS as a principal surrogate to predict the treatment effect
on the endpoint using the treatment effect on the surrogate. They assumed that the true endpoint
does not depend on the treatment among subjects whose surrogate is the same under treatment
and control, i.e., the causal necessity holds. However, the causal necessity used by Baker et al.
(2012) has not been verified by either previous studies or observed data.
For the ACCTs data, the monotonicity assumption requiring nonnegative individual causal
effect on the surrogate may not hold, because the treatment may have negative side-effects on
the surrogate for some patients. Second, the exclusion restriction assumption implies the causal
necessity, which is the scientific question of interest in evaluating surrogate endpoints. Third,
Gaussian mixture models are not applicable to the binary endpoints in the ACCTs data. The meta-
analysis approaches (Daniels and Hughes, 1997; Li et al., 2011; Baker et al., 2012) may also suffer
from the surrogate paradox (VanderWeele, 2013). When the monotonicity or exclusion restriction
assumption does not hold, Ding et al. (2011), Mealli and Pacini (2013), and Yang and Small
(2015) achieved partial and point identification of principal causal effects by exploiting covariates or
secondary outcomes, and Mattei et al. (2013) improved Bayesian inference for principal causal effects
using multiple outcomes. However, when additional outcomes or covariates are not available, we
cannot identify causal effects using previous approaches. Without identifiability, Bayesian inference
is sensitive to prior distributions (Gustafson, 2009).
In this paper, we propose approaches to identifying the principal stratification causal effects
without the exclusion restriction assumption and further without the monotonicity assumption. To
remove the exclusion restriction assumption, we need at least two trials. Furthermore, to remove
the monotonicity assumption, we give a sufficient condition for the local identifiability of the causal
effects, which requires at least three trials. We first assume that these trials are homogeneous. Using
the identified principal stratification causal effects, we can test the causal necessity and the causal
sufficiency of a surrogate. We evaluate the treatment effect on the unobserved endpoint in a new
trial where the distribution of principal strata and/or the treatment may be different from those
in the validation trials. We then propose criteria for surrogates that avoid the surrogate paradox.
Allowing for possible deviations from the homogeneity assumption, we then conduct a sensitivity
analysis based on a class of Bayesian hierarchical models. We apply the proposed approaches to
the ACCTs data and evaluate the surrogacy of DFS with three-year follow-up for OS with five-year
follow-up.
The paper proceeds as follows. We introduce the notation and assumptions in Section 2. We
present the identification conditions with and without the monotonicity assumption in Section 3.
Section 4 discusses the evaluation of surrogate based on principal stratification. We evaluate the
performance of our approaches with finite sample sizes in Section 5 via simulation studies. We
apply our approaches to the ACCTs data in Section 6, and perform a sensitivity analysis using
Bayesian hierarchical models in Section 7. We conclude with a discussion in Section 8. We present
the details of the proofs and computations in the online supporting materials, and provide the data
and compute code online.
2. Notation and assumptions
2.1. Potential outcomes and principal stratification
Suppose that there are NR independent trials which have the same treatment and the same control.
Let R denote the trial number taking values from 1 to NR. Let Z be a binary treatment assignment
with Z = 1 for treatment and 0 for control. Let S denote a binary surrogate and Y a binary endpoint
of interest. In the ACCTs data, Si = 0 if the cancer of patient i reoccurred before 3 years, and Si = 1
otherwise. The endpoint Yi denotes the survival status within 5 years, with Yi = 1 for “survival”
and Yi = 0 for “dead.” We use the potential outcomes framework to define causal effects and make
the Stable Unit Treatment Value Assumption (SUTVA) throughout the paper, i.e., there is only
one version of the potential outcomes and there is no interference between units (Rubin, 1980). The
SUTVA allows us to uniquely define the potential outcomes Si(z) and Yi(z) for the surrogate and
the endpoint variables if patient i were to receive treatment z for z = 0 and 1. The observed values of
S and Y are deterministic functions of both the treatment assignment and the potential outcomes,
i.e., Si = Si(Zi) = ZiSi(1) + (1− Zi)Si(0) and Yi = Yi(Zi) = ZiYi(1) + (1− Zi)Yi(0). Throughout
our paper, we assume that {(Ri, Zi, Si(1), Si(0), Yi(1), Yi(0)) : i = 1, . . . , N} are independently and
identically distributed (iid) samples drawn from an infinite super-population, and thus the observed
{(Ri, Zi, Si, Yi) : i = 1, . . . , N} are also iid. Although we will discuss only the binary endpoints
in depth, our framework and approaches are also applicable to general continuous endpoints by
dichotomizing the endpoints to identify the distributional causal effects.
Frangakis and Rubin (2002) defined principal stratification using the joint potential outcomes
of the surrogate under both treatment and control, i.e., Ui = (Si(1), Si(0)). For simplicity, we
relabel the possible values of U , (1, 1), (1, 0), (0, 1) and (0, 0), as ss, ss¯, s¯s and s¯s¯, respectively. In
our motivation example, we use “s” for “disease-free survival in three-year follow-up,” and “s¯”
otherwise. We are interested in the principal stratification average causal effects (PSACEs) for
each trial, defined as
ACEur = E{Y (1)− Y (0) | U = u,R = r}
for u = ss, ss¯, s¯s, s¯s¯, and r = 1, . . . , NR. Based on the PSACEs, we can formally define the causal
necessity and causal sufficiency (Gilbert and Hudgens 2008).
Definition 1. Causal necessity requires ACEur = 0 for u = ss, s¯s¯, and causal sufficiency
requires ACEur 6= 0 for u = ss¯, s¯s, where r = 1, . . . , NR.
The above definition of causal necessity is weaker than the usual exclusion restriction assumption
(Angrist et al., 1996) that requires zero individual causal effect on the outcome for principal strata
u = ss and s¯s¯.
2.2. Assumptions
In this subsection, we introduce the basic assumptions, which are commonly used in causal inference.
By identification of parameters, we mean that they can be expressed as functions of the distributions
of observed variables. We let A B | C denote the conditional independence of A and B given C.
Assumption 1. (Randomization). Z {S(1), S(0), Y (1), Y (0)} | R.
Assumption 1 means that treatment assignment Z is randomized within each trial, but the
assignment probabilities may be different. Because we have independent randomized clinical trials
in the ACCTs data, Assumption 1 holds by the designs of experiments.
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The following monotonicity assumption is widely used for principal stratification analysis (An-
grist et al., 1996) and principal surrogate evaluation (Gilbert and Hudgens, 2008).
Assumption 2. (Monotonicity). Si(1) ≥ Si(0) for each individual i.
Assumption 2 means that the treated surrogate endpoint Si(1) is always better than or equal
to the controlled surrogate endpoint Si(0) for every patient i. The monotonicity assumption may
be too restrictive for some real applications where treatment may have negative side-effects on
some patients. We shall discuss the identification of PSACEs with and without the monotonicity
assumption separately.
Let O(z, s) denote the set of principal strata that are compatible with the observed values
Zi = z and Si = s. Then we have O(1, 1) = {ss, ss¯}, O(1, 0) = {s¯s¯, s¯s}, O(0, 1) = {ss, s¯s}, and
O(0, 0) = {ss¯, s¯s¯} without the monotonicity assumption. The monotonicity assumption eliminates
the stratum s¯s, and therefore O(1, 1) = {ss, ss¯}, O(1, 0) = {s¯s¯}, O(0, 1) = {ss}, and O(0, 0) =
{ss¯, s¯s¯}. Although the principal stratification variable U is not observable for all units, monotonicity
allows us to identify the proportions of principal strata using the distribution of the observed data.
Define
piur = P (U = u | R = r),
which can be identified by pis¯s¯,r = P (S = 0 | Z = 1, R = r), piss,r = P (S = 1 | Z = 0, R = r) and
piss¯,r = 1 − piss,r − pis¯s¯,r. With monotonicity, we can also identify the expectations E{Y (0) | U =
ss,R = r} = E(Y | Z = 0, S = 1, R = r) and E{Y (1) | U = s¯s¯, R = r} = E(Y | Z = 1, S = 0, R =
r). Since patients within the observed group (Z = 1, S = 1) or (Z = 0, S = 0) are both mixtures
of two latent principal strata, we cannot identify the PSACEs without further assumptions beyond
Assumptions 1 and 2. We can obtain large sample bounds for the PSACEs from the observed data,
but these bounds are barely informative as shown in the online Appendix.
3. Identification of the PSACEs from multiple trials
Because the principal stratum is unobservable, causal effects within principal strata are not iden-
tifiable in general. In this section, we shall propose approaches to improving the identifiability of
the PSACEs in terms of multiple trials. To combine information from multiple trials, we make the
following homogeneity assumption.
Assumption 3. (Homogeneity). R Y (z) | U for z = 0, 1.
The homogeneity assumption means that the potential outcome Y (z) may depend on the prin-
cipal stratum U , but is independent of the trial number R conditional on the principal stratum
U . Thus, there is no “direct effect” of R on Y (z) within the principal stratum U . We can include
pretreatment covariates X to make this assumption more plausible, i.e., R Y (z) | (U,X), and we
omit it for simplicity. As an example, Assumption 3 for the ACCTs data means that the survival
of a patient under treatment or control does not depend on which trial he/she is in once we know
his/her principal stratum U , defined by the reoccurrence of cancer under both treatment and con-
trol. In particular, for the patients in stratum U = ss, the cancer will not reoccur within 3 years no
matter whether they receive the treatment or not. Thus the principal stratum can be interpreted
as a measure of the physical status of a patient. It may be plausible that the survival will no
longer depend on the trial number after we know a patient’s physical status and the cancer status.
Recognizing that Assumption 3 may not be directly testable and may be violated in practice, we
propose an approach for conducting sensitivity analysis about Assumption 3 in Section 7.
The following result further explains the homogeneity of causal effects across trials.
Proposition 1. Under Assumption 1, Assumption 3 is equivalent to R Y | (U,Z), which
implies ACEur = ACEur′ for all u = ss, ss¯, s¯s, s¯s¯ and r 6= r′.
By Proposition 1, we can write ACEu = ACEur, and thus we can discuss the identifiability of
the common PSACEs using the data from multiple trials together.
To simplify the notation, we define pr = P (R = r) as the proportion of trial r, αr = P (Z =
1 | R = r) as the proportion of patients receiving treatment in trial r, δzur = P (Y = 1 | Z =
z, U = u,R = r) as the survival proportion conditional on the treatment z, principal stratum u
and trial number r. Under the homogeneity assumption, we have that δzu = δzur. We further
define p = {pr : r = 1, . . . , NR}, α = {αr : r = 1, . . . , NR}, pir = {piss,r, piss¯,r, pis¯s¯,r, pis¯s,r},
pi = {pir : r = 1, . . . , NR}, and δ = {δzu : z = 0, 1;u = ss, ss¯, s¯s¯, s¯s}. Under monotonicity, we do
not have the parameters δz,s¯s, and we have pis¯s,r = 0.
3.1. Identification with monotonicity
In addition to the homogeneity assumption, we need the following assumption.
Assumption 4. (a) There exist at least two trials r1 and r2, such that piss,r1/piss¯,r1 6= piss,r2/piss¯,r2 .
(b) There exist at least two trials r3 and r4, such that piss¯,r3/pis¯s¯,r3 6= piss¯,r4/pis¯s¯,r4 .
Again, treating the principal stratum as a measure of patients’ physical status, Assumption 4
means that patients in different trials have different distributions of the patients’ physical status.
Under monotonicity, Assumption 4 is testable by data because we can identify the proportions of
the principal strata under Assumption 2 as shown in Section 2.2.
The trial number R acts like an instrumental variable associated with U in the sense that
Assumption 3 is similar to the exclusion restriction assumption, and Assumption 4 guarantees the
association between R and U . Under Assumptions 3 and 4, there is no “direct effect” of R on
Y , which is similar to the instrumental variable case where the instrumental variable does not
“directly” affect the outcome.
Theorem 1. Under Assumptions 1 to 3, we have that, for u = ss, ss¯ and s¯s¯,
(a) P (Y = 1 | Z = 1, U = u) for all principal strata u are identifiable if Assumption 4(a) holds;
(b) P (Y = 1 | Z = 0, U = u) for all principal strata u are identifiable if Assumption 4(b) holds;
(c) ACEu for all principal strata u are identifiable if both Assumptions 4(a) and 4(b) hold.
Assumption 4 requires at least two independent trials for the identifiability. We can use any
two trials satisfying Assumption 4 to obtain moment estimators, and we can also use all trials to
obtain more efficient maximum likelihood estimates (MLEs). The following example illustrates the
identifiability for the case with two independent trials (NR = 2) under Assumptions 1 to 4.
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Example 1. First, the proportions of the principal strata piur are identifiable under monotonic-
ity, as discussed in Section 2.2.
Second, the probability ωys|zr = P (Y = y, S = s | Z = z,R = r) can be identified from
the observed data. We can directly identify two outcome distributions δ1,s¯s¯ = ω10|11/pis¯s¯,1 and
δ0,ss = ω11|01/piss,1.
Third, if piss,1/piss¯,1 6= piss,2/piss¯,2, we have from the proof of Theorem 2 that
δ1,ss =
ω11|11 · piss¯,2 − ω11|12 · piss¯,1
piss,1 · piss¯,2 − piss,2 · piss¯,1 , δ1,ss¯ =
ω11|12 · piss,1 − ω11|11 · piss,2
piss,1 · piss¯,2 − piss,2 · piss¯,1 .
If piss,1/piss¯,1 6= piss,2/piss¯,2, we have from the proof of Theorem 2 that
δ0,ss¯ =
ω10|01 · pis¯s¯,2 − ω10|02 · pis¯s¯,1
piss¯,1 · pis¯s¯,2 − piss¯,2 · pis¯s¯,1 , δ0,s¯s¯ =
ω10|02 · piss¯,1 − ω10|01 · piss¯,2
piss¯,1 · pis¯s¯,2 − piss¯,2 · pis¯s¯,1 .
3.2. Identification without monotonicity
Monotonicity for every individual may be too restrictive in practice. In this subsection, with the
help of more than two independent trials, we can remove monotonicity.
By the homogeneity assumption, the probabilities of the observed data can be decomposed as
P (Z = z, S = s, Y = y | R = r)
=
∑
u∈O(z,s)
P (Z = z | R = r) · piur · P (Y = y | Z = z, U = u), (1)
for z, s, y = 0, 1. Let ξ = (p,α,pi, δ) denote the vector of the parameters. Let f be the vector
of probabilities on the left-hand side of equation (B.1). Applying a Taylor expansion, we can
approximate f(ξ) by linear equations of ξ around the true parameters ξ0, i.e., f(ξ) ≈ f(ξ0)+∇f |ξ0
(ξ − ξ0), where ∇f |ξ0 is the Jacobian matrix with the (i, j)-th element ∂fi/∂ξj |ξ0 . According to
Roche et al. (1997), a distribution FW (w; ξ) of a random variable W is locally identifiable at ξ0 if
there exists some neighborhood N(ξ0) of ξ0 such that for all ξ ∈ N(ξ0), FW (w; ξ0) = FW (w; ξ)
for all w if and only if ξ = ξ0. Therefore, under the randomization and homogeneity assumptions,
the parameter vector ξ can be represented by a function of the distributions of observed variables
and thus it is locally identifiable if the Jacobian matrix ∇f |ξ0 is of full column rank. In fact,
Assumption 4 is a necessary condition for ∇f |ξ0 to be full column rank. In practice, the full rank
condition of ∇f |ξ0 can be tested empirically by the rank of ∇f |ξˆ, where ξˆ is the MLE of ξ0
(Goodman, 1974; Skrondal and Rabe-Hesketh, 2004).
A necessary condition for local identifiability of unknown parameters is that the number of
observed frequencies is larger than the number of unknown parameters. For this case, we have the
following result.
Proposition 2. Under Assumptions 1 and 3, a necessary condition for the local identifiability
of the joint distribution of (Y, Z, S, U,R) is NR ≥ 3.
Intuitively, when NR ≤ 2, there will be less equations than unknown parameters in the equations
in (B.1), and thus we cannot obtain unique solution of the unknown parameters. Therefore, there
must be at least three independent trials to identify the PSACEs without monotonicity. In the case
without monotonicity, we can not obtain closed forms of PSACEs like Example 1, because we are
not able to obtain closed forms of piur’s. We can use a numerical approach to calculate the PSACEs,
and we give an example in the online Appendix to illustrate the identifiability for the case without
monotonicity.
Without monotonicity, we can prove only local identification. If a parameter is locally identifiable
but not globally identifiable, its posterior distribution must be multimodal and has the same value
at multiple modes. Thus, we can check its posterior distribution to verify identifiability. In our
simulation studies and application, posterior distributions of all the parameters are unimodal, which
means that the parameters are indeed globally identifiable. In general, we can test whether the
posterior distributions of parameters are unimodal using existing methods.
3.3. Computation, model checking, and goodness-of-fit tests
In this subsection, we shall discuss the estimation of the parameters. We can use the expectation-
maximization (EM) algorithm and the Gibbs Sampler to compute the MLEs and simulate the
posterior distributions of PSACEs. Suppose that R follows a categorical distribution with param-
eter p, Z follows Bernoulli distributions conditional on R with parameter α, U follows categorical
distributions conditional on R with parameter pi, and Y follows Bernoulli distributions conditional
on Z and U with parameter δ. The unobserved variable U is treated as a latent variable. The
complete data can be represented by a contingency table classified by (Z,U, Y,R), and the ob-
served data can be represented by a contingency table classified by (Z, S, Y,R) with cell counts
Nzsyr = #{i : Zi = z, Si = s, Yi = y,Ri = r}. For Bayesian inference, we use Dirichlet (or Beta)
distributions with parameters (1, . . . , 1) as the non-informative prior distributions of p, α, pi and
δ. Computational details are given in the online Appendix.
More interestingly, when NR ≥ 2 with monotonicity or NR ≥ 3 for without monotonicity,
the extra degrees of freedom allow us to perform goodness-of-fit tests based on the asymptotic
distributions of the likelihood ratio statistics:
Tm(Nzsyr) = 2 log
L(ζˆs | Nzsyr)
L(ξˆm | Nzsyr)
a∼ χ24NR−6,
Tnm(Nzsyr) = 2 log
L(ζˆs | Nzsyr)
L(ξˆnm | Nzsyr)
a∼ χ23NR−8,
where ζˆs is the MLE under the saturated model, i.e., (Z, S,R, Y ) follows the multinomial distribu-
tion without constraints on parameters, and ξˆm and ξˆnm are the MLEs with and without monotonic-
ity. The degrees of freedom with and without monotonicity are (8NR−1)− (4NR + 5) = (4NR−6)
and (8NR − 1) − (5NR + 7) = (3NR − 8), respectively. On the other hand, we can use Bayesian
posterior predictive p-values (ppp) for model checking (Rubin, 1984; Meng, 1994). Let N repzsyr denote
the replicate data generated from their posterior predictive distributions. The ppp’s for the models
with and without monotonicity are
pppm = P{Tm(Nzsyr) > Tm(N repzsyr) | Nzsyr},
pppnm = P{Tnm(Nzsyr) > Tnm(N repzsyr) | Nzsyr},
which can be approximated by the posterior draws from the Gibbs Sampler.
Principal stratification estimation and surrogate endpoint evaluation 9
4. Evaluation of surrogate based on principal stratification
In the previous section, we proposed approaches to identifying the PSACEs using multiple trials.
In this section, our goal is to predict the treatment effect on the endpoint both quantitatively and
qualitatively, based on the treatment effect on the surrogate in a new trial without observing the
endpoint. We consider two cases for applying the principal surrogate to a new trial in which the
endpoint is not observed.
Case 1. The surrogate is applied to a new population where the treatment is the same, but the
distribution of principal strata differs from the validation trials. For example, in validation
trials, we study the effect of drug A on cardiovascular disease, and use an indicator for
whether the level of cholesterol increases as a candidate surrogate. Based on the PSACEs
estimated from validation trials, we use the surrogate to predict the effect of the drug A
on the disease of patients in a different population.
Case 2. The surrogate is applied to a new population where both the treatment and the distribution
of principal strata may be different from those in the validation trials. For example, based
on the PSACEs for drug A estimated from validation trials, we use the surrogate to predict
the effect of a new drug B on the disease of patients in a different population.
For quantitative evaluation, we assume that the PSACEs are the same across the validation
trials and the new trial, then try to calculate the treatment effect on the endpoint. For qualitative
evaluation, we relax this assumption so that the PSACEs have the same signs across the validation
trials and the new trial. Then we try to get the sign of the the treatment effect on the endpoint.
VanderWeele (2013) points out that a principal surrogate satisfying the causal necessity (ACEu =
0 for u = ss, s¯s¯) and the causal sufficiency (ACEu 6= 0 for u = ss¯, s¯s) may not avoid the surrogate
paradox. In the following example, we further illustrate that a principal surrogate verified in a val-
idation trial may not be used to correctly evaluate the treatment effect on the unobserved endpoint
in a new trial, even if the new trial and the validation trials have the same PSACEs.
Example 2. Consider a surrogate S which is evaluated by validation trial r. The surrogate
satisfies the causal necessity with ACEss = ACEs¯s¯ = 0, and the causal sufficiency with ACEss¯ = 0.4
and ACEs¯s = −0.6. Suppose that the distribution of principal strata in the validation trial is
piss,r = pis¯s¯,r = 0.2, piss¯,r = 0.4 and pis¯s,r = 0.2. Then we have E{S(1)−S(0) | R = r} = 0.2 > 0 and
E{Y (1)−Y (0) | R = r} = 0.04 > 0, which means that the surrogate paradox is avoided in validation
trial r. Now suppose that a new trial R = r′ has the same PSACEs as the validation trial. But
the distribution of principal strata differs: piss,r′ = 0.1, pis¯s¯,r′ = 0.2, piss¯,r′ = 0.4, and pis¯s,r′ = 0.3.
Then we have E{S(1)− S(0) | R = r′} = 0.1 > 0 but E{Y (1)− Y (0) | R = r′} = −0.02 < 0. The
surrogate paradox arises, and thus we cannot use the surrogate S to correctly evaluate the treatment
effect on the endpoint Y in the new trial.
Now we discuss the conditions to avoid the surrogate paradox when a validated surrogate is
applied to a new trial with a new treatment or a new population. Let ACESr = E{S(1) − S(0) |
R = r} and ACEYr = E{Y (1)− Y (0) | R = r}. Without loss of generality, we assume ACESr > 0.
For the case with ACESr < 0, we can redefine the surrogate as S
∗ = 1 − S. Below we give the
relationships among the average causal effects ACESr , ACE
Y
r and ACEur for trial r.
Proposition 3. For trial r, we assume that the surrogate satisfies the causal necessity.
(i) With monotonicity, we have ACEYr = ACE
S
r ×ACEss¯,r.
(ii) Without monotonicity, suppose ACESr > 0, we have the lower and upper bounds of ACE
Y
r :
if ACEss¯,r +ACEs¯s,r ≥ 0,
ACESr ×ACEss¯,r ≤ ACEYr ≤ (ACEss¯,r +ACEs¯s,r)/2 +ACESr × (ACEss¯,r −ACEs¯s,r)/2,
and otherwise
(ACEss¯,r +ACEs¯s,r)/2 +ACE
S
r × (ACEss¯,r −ACEs¯s,r)/2 ≤ ACEYr ≤ ACESr ×ACEss¯,r.
Proposition 3 shows the relationships between the treatment effect on the surrogate and the
treatment effect on the endpoint, which immediately give us the following implication relationships
when the endpoint Y is unobservable.
Corollary 1. For trial r, we assume that the surrogate satisfies the causal necessity and
ACEss¯,r > 0.
(i) With monotonicity, ACESr > 0 (or = 0) implies ACE
Y
r > 0 (or = 0).
(ii) Without monotonicity, ACEss¯,r +ACEs¯s,r ≥ 0 and ACESr > 0 imply ACEYr > 0.
In Corollary 1(i), with monotonicity, a principal surrogate satisfying the causal sufficiency can
avoid the surrogate paradox. Without monotonicity, the above result (i) does not hold since the
causal effects on the endpoint Y may be different in the principal strata u = ss¯ and s¯s. Thus, we
require the condition ACEss¯,r + ACEs¯s,r ≥ 0 in (ii) of Corollary 1, i.e., the positive causal effect
on the endpoint in stratum ss¯ can offset the negative causal effect on the endpoint in stratum s¯s.
Proposision 3 and Corollary 1 can help us to assess the treatment effect on the endpoint in a
new trial both quantitatively and qualitatively. Below we illustrate this with Examples 3 and 4 for
Cases 1 and 2 respectively.
Example 3. Suppose that in the validation trial, we studied drug A and obtained estimates
ACEss,r = ACEs¯s¯,r = 0, ACEss¯,r = 0.5 and ACEs¯s,r = −0.4. For Case 1, we are aiming to
evaluate the effect of the same drug on the disease for a different population in a new trial r′. In
trial r′, we obtain E{S(1) | R = r′} = 0.6 and E{S(0) | R = r′} = 0.4. If we assume that the
PSACEs in the new trial are the same as those in the validation trial and monotonicity holds in
the new trial, Proposition 3(i) implies that
ACEYr′ = ACE
S
r′ ×ACEss¯,r′ = ACESr′ ×ACEss¯,r = (0.6− 0.4)× 0.5 = 0.10 > 0.
If monotonicity fails in the new trial, we can still calculate the bounds for ACEYr′ according to
Proposition 3(ii):
ACEYr′ ≤ (ACEss¯,r′ +ACEs¯s,r′)/2 +ACESr′ × (ACEss¯,r′ −ACEs¯s,r′)/2
= (0.5− 0.4)/2 + (0.6− 0.4)× (0.5 + 0.4)/2 = 0.14, (2)
ACEYr′ ≥ ACESr′ ×ACEss¯,r′ = (0.6− 0.4)× 0.5 = 0.10. (3)
If we only assume that ACEss,r′ = ACEs¯s¯,r′ = 0 and ACEss¯,r′ +ACEs¯s,r′ > 0 in the new trial as
in the validation trial, then ACESr′ = 0.2 > 0 and ACEss¯,r′ = 0.5 > 0 imply ACE
Y
r′ > 0, according
to Corollary 1 with or without monotonicity.
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Example 4. Suppose that in the validation trial, we studied drug A and estimated ACEss,r =
ACEs¯s¯,r = 0, ACEss¯,r = 0.5 and ACEs¯s,r = −0.4. For Case 2, we are aiming to evaluate the
effect of another drug B on the disease for the population in a new trial r′. Unlike Case 1, we need
to define the new drug as Z ′, the principal stratification as U ′ = (S(Z ′ = 1), S(Z ′ = 0)), and the
PSACEs as ACEur′ = E{Y (Z ′ = 1) − Y (Z ′ = 0) | U ′ = u,R = r′}. In the new trial, we obtain
E{S(1) | R = r′} = 0.6 and E{S(0) | R = r′} = 0.4. Similar to Example 3, if we assume that the
PSACEs in the new trial are the same as those in the validation trial and monotonicity holds in
the new trial, we can calculate ACEYr′ = 0.1. If monotonicity fails, we can obtain the bounds (2)
and (3) for ACEYr′ . If we assume ACEss,r′ = ACEs¯s¯,r′ = 0 and ACEss¯,r′ + ACEs¯s,r′ > 0 as in
Example 3, we can deduce that ACEYr′ > 0 according to Corollary 1.
Assuming the same values of PSACEs enables us to quantitatively evaluate the surrogate, and
only assuming the same signs of PSACEs still allows us for qualitative evaluation. Note that we
give only the sufficient conditions to evaluate the surrogate in a new trial. The plausibilities of
these assumptions depend on subject knowledge and experts’ opinions.
5. Simulation studies
In this section, we conduct simulation studies to evaluate finite sample performances of our proposed
approaches, under both correctly specified and misspecified models.
5.1. Estimation under the models with homogeneity
We show the simulation results of the MLEs and the credible intervals of the PSACEs with and
without monotonicity. The 95% credible intervals are obtained by the Gibbs Sampler with 20, 000
iterations and the first 4, 000 iterations as the burn-in period. We repeat 200 times to get the
coverage proportions of the true PSACEs for each setting. We use three different sample sizes, and
let N denote the average sample size for each trial, i.e., N = total sample size/NR. In Figures 1(a)
and 1(b), we show the biases and root mean squared errors (RMSEs) of the MLEs and the coverage
proportions of the posterior credible intervals only for ACEss. The results for other principal strata
are similar and shown in the online Appendix.
First, with monotonicity, we generate R from a categorical distribution with pr = 1/NR for all r.
We generate Z from Bernoulli distributions conditional on R with different conditional probabilities,
α, allowing for different treatment assignment probabilities for different trials. We generate U from
categorical distributions conditional on R with probabilities (piss,r, piss¯,r, pis¯s¯,r) for trial r. In order
to satisfy Assumption 4, we choose U | R = r to depend on R = r. We generate three scenarios
with NR = 2, 3 and 5, and present the true values of (piss,r, piss¯,r, pis¯s¯,r) and α in the upper panel
of Table 1. We generate Y from Bernoulli distributions with the following conditional probabilities
given Z and U :
(δ1,ss, δ0,ss, δ1,ss¯, δ0,ss¯, δ1,s¯s¯, δ0,s¯s¯) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1),
with PSACEs ACEss = 0.3, ACEss¯ = 0.4, and ACEs¯s¯ = 0.5.
We show the simulation results in Figure 1(a), where the numbers “2,” “3” and “5” denote the
numbers of trials. The biases are small for all scenarios, the RMSEs decrease as the sample size
and the number of trials increase, and the coverage proportions are close to 95% for all scenarios.
Comparing the 6th point with the 7th point in the second subplot of Figure 1(a), we can see that the
Table 1. True parameters in simulations. We present the values of piur = P (U = r | R = r)
and αr = P (Z = 1 | R = r) in each scenario. The upper panel shows the true parameters
with monotonicity, and the lower panel shows the true parameters without monotonicity.
With monotonicity
NR = 2 NR = 3 NR = 5
(piss,r, piss¯,r, pis¯s¯,r) αr (piss,r, piss¯,r, pis¯s¯,r) αr (piss,r, piss¯,r, pis¯s¯,r) αr
r = 1 (0.7, 0.2, 0.1) 0.4 (0.8, 0.1, 0.1) 0.4 (0.8, 0.1, 0.1) 0.3
r = 2 (0.1, 0.2, 0.7) 0.6 (0.1, 0.8, 0.1) 0.5 (0.6, 0.3, 0.1) 0.4
r = 3 (0.1, 0.1, 0.8) 0.6 (0.3, 0.2, 0.5) 0.5
r = 4 (0.1, 0.3, 0.6) 0.6
r = 5 (0.1, 0.1, 0.8) 0.7
Without monotonicity
NR = 3 NR = 4 NR = 5
(piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) αr (piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) αr (piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) αr
r = 1 (0.6, 0.2, 0.1, 0.1) 0.4 (0.6, 0.2, 0.1, 0.1) 0.4 (0.6, 0.2, 0.1, 0.1) 0.3
r = 2 (0.1, 0.6, 0.2, 0.1) 0.5 (0.1, 0.6, 0.2, 0.1) 0.5 (0.1, 0.6, 0.2, 0.1) 0.4
r = 3 (0.1, 0.1, 0.6, 0.2) 0.6 (0.1, 0.1, 0.6, 0.2) 0.6 (0.3, 0.2, 0.3, 0.2) 0.5
r = 4 (0.2, 0.3, 0.2, 0.3) 0.7 (0.4, 0.1, 0.4, 0.1) 0.6
r = 5 (0.1, 0.1, 0.6, 0.2) 0.7
RMSE of the case with (NR = 2, N = 500) is smaller than that of the case with (NR = 5, N = 200).
The total sample sizes for these two cases are the same, while the case of the 6th point has more
parameters (more piur’s with more trials). The simulation is consistent with our intuition that more
parameters will result in a larger RMSE.
Next, without monotonicity, we generate R from a categorical distribution with pr = 1/NR for
all r. We generate Z from Bernoulli distributions with conditional probabilities α, and U from
categorical distributions both conditional on R with probabilities (piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) for trial
r. For this case without monotonicity, the necessary condition for identifiability is NR ≥ 3. Thus we
generate three scenarios with NR = 3, 4 and 5, and present the true values of (piss,r, piss¯,r, pis¯s¯,r, pis¯s,r)
and α in the lower panel of Table 1. We generate Y from Bernoulli distributions with conditional
probabilities given U and Z as
(δ1,ss, δ0,ss, δ1,ss¯, δ0,ss¯, δ1,s¯s¯, δ0,s¯s¯, δ1,s¯s, δ0,s¯s) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2),
with PSACEs ACEss = 0.3, ACEss¯ = 0.4, ACEs¯s¯ = 0.5, and ACEs¯s = 0.3.
We show the simulation results in Figure 1(b), where “3,” “4” and “5” denote the numbers of
trials. The biases and the coverage proportions are similar to the cases with monotonicity. But the
RMSEs become a little larger than those with monotonicity. The performances of our approaches
are quite promising for the sample size N = 500 × NR, comparable to the ACCTs data set in
Section 6.
5.2. Simulations under the models without homogeneity
We conduct simulation studies when the homogeneity assumption is false with δzur dependent on
r. Let d be a measure of heterogeneity. We simulate three cases for different levels of heterogeneity
with d = 0.01, 0.025 and 0.05. For each case, we conduct simulation studies when NR = 3 both
with and without monotonicity.
With monotonicity, we first generate (Z,U) the same as the scenario with NR = 3 in the
upper panel of Table 1. To allow heterogeneity, we let δzu1 = µzu − (−1)zd, δzu2 = µzu and
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δzu3 = µzu + (−1)zd, with δzur varying with r. The corresponding mean vector is
(µ1,ss, µ0,ss, µ1,ss¯, µ0,ss¯, µ1,s¯s¯, µ0,s¯s¯) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1).
Then we have ACEu1 = µ1u − µ0u + 2d, ACEu2 = µ1u − µ0u and ACEu3 = µ1u − µ0u − 2d. A
larger d results in a larger violation of the homogeneity assumption.
Similarly, without monotonicity, we first generate (Z,U) the same as the scenario with NR = 3
in the lower panel of Table 1. Then we let δzu1 = µzu−(−1)zd, δzu2 = µzu and δzu3 = µzu+(−1)zd,
with the corresponding mean vector
(µ1,ss, µ0,ss, µ1,ss¯, µ0,ss¯, µ1,s¯s¯, µ0,s¯s¯, µ1,s¯s, µ0,s¯s) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2).
Then we have ACEu1 = µ1u − µ0u + 2d, ACEu2 = µ1u − µ0u, and ACEu3 = µ1u − µ0u − 2d.
For all the evaluations, we use the mean parameters µzu as the “true parameters.” Figures
1(c) and 1(d) show the results for ACEss including the biases, the RMSEs of the MLEs and the
coverage proportions of the posterior credible intervals, where “1,” “2” and “3” correspond to the
cases of d = 0.01, 0.025 and 0.05, respectively.
Comparing Figures 1(a) and 1(b) under the homogeneity assumption with Figures 1(c) and
1(d) without the homogeneity assumption, we find that the biases increase as d increases, and do
not decrease as the sample size grows. The RMSEs increase and the coverage proportions of 95%
credible intervals decrease as d increases, especially for large sample sizes. This means that the
point and interval estimates are sensitive to the heterogeneity of trials. Thus, we will propose an
approach for sensitivity analysis, and apply it to our real application in Section 7.
6. Application to the ACCTs data
For the ACCTs, the OS with five-year follow-up (survival status within 5 years) is used as the
endpoint in most earlier papers to evaluate a particular treatment regimen. However, this endpoint
requires five-year follow-up. The goal of the ACCTs study is to explore whether DFS with three-
year follow-up (cancer reoccurred before 3 years) is a valid surrogate for the OS with five-year
follow-up. The data contain more than 20, 000 patients and 18 randomized III clinical trials. The
period of trial enrollment spans from 1977 to 1999. The data of 10 of the randomized trials are
available from Baker et al. (2012). Baker et al. (2012) transformed the survival data into counts for
binary outcomes. As a result, in each trial, we have a contingency table of observed frequencies with
three variables: the treatment (Z), DFS (S) and OS (Y ). To illustrate our approaches, we assume
all the trials have the same treatment and control, although we do not know the exact treatment
and control in each trial. This may influence the plausibility of the homogeneity assumption, and
thus we will conduct a sensitivity analysis in Section 7. We show all the bound analysis in the
online Appendix, and find that the bounds are barely informative. In this section, we apply the
proposed approaches to the ACCTs data to obtain point identifications of the treatment effects on
the endpoint OS within principal strata defined by the potential DFS. We postpone the sensitivity
analysis to Section 7.
6.1. Results with monotonicity
We use the Gibbs Sampler to simulate the posterior distributions of the PSACEs, because it is
very direct to obtain posterior credible intervals for the PSACEs from draws of the Gibbs Sampler.
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Fig. 1. Simulations for homogeneity (a) and (b) and heterogeneity (c) and (d). Each subgraph presents the
bias, RMSE, coverage proportions of the 95% credible intervals of ACEss. Nine combinations of NR and N
are shown in (a) and (b); and nine combinations of N and d (“1” for .01, “2” for .025, “3” for .05) are shown in
(c) and (d).
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After 100,000 iterations with 50,000 used as burn-in, the Markov chains converge very well with
Gelman–Rubin diagnostic statistics approximately equal to 1 from five independent chains. Figure
2(a) shows the histograms of the posterior draws of the PSACEs under monotonicity. The posterior
median of ACEs¯s¯, −0.008, is small, and its 95% credible interval covers zero. Although the posterior
median of ACEss, 0.032, is also small, its 95% credible interval does not cover zero. If we would
like to believe monotonicity, there exists a “principal stratification direct effect” of the treatment
on the endpoint for stratum ss but not for stratum s¯s¯, and thus the causal necessity is not well
satisfied. Because ACEss¯ is significantly nonzero with posterior median 0.583 and 95% credible
interval (0.235, 0.787), and the treatment is effective on the surrogate with posterior medians of
ACESr greater than 0.022 in all trials, we can conclude that it is also effective on the endpoint
according to Corollary 1 (i).
6.2. Results without monotonicity
Figure 2(b) shows the histograms of posterior draws of the PSACEs without monotonicity. First,
ACEss and ACEs¯s¯ are very close to zero with posterior medians 0.014 and 0.001 and 95% credible
intervals covering zero. When the treatment does not affect the DFS with three-year follow-up,
it will not affect the OS with five-year follow-up. Second, ACEss¯ and ACEs¯s are significantly
different from zero with posterior medians 0.774 and −0.750 and 95% credible intervals excluding
zero. Therefore, when the treatment affects the DFS with three-year follow-up, it will also affect
the OS with five-year follow-up. The results without monotonicity differ from the results with
monotonicity in the posterior distribution of ACEss, which give us different interpretations about
the causal mechanism. From a practical point of view, we need to verify which model is more
plausible based on the observed data.
6.3. Model comparison and checking
We use the methods described in Section 3.3 to perform model comparison. The ppp’s are 0.039
and 0.470 under the models with and without monotonicity, respectively. Analogously, the p-values
from the likelihood ratio tests are 0.015 and 0.140 under the models with and without monotonicity,
respectively. Therefore, the model with monotonicity is not compatible with the observed data, and
it is rejected by both frequentists’ and Bayesian methods. Furthermore, the lower right subplot of
Figure 2(c) shows that the posterior medians and 95% credible intervals of pis¯s,r under the model
without monotonicity are far from zero in many trials. On the contrary, the large p-values from both
the likelihood ratio test and the posterior predictive check indicate very good fit of the model without
monotonicity to the observed data. Although previous methods often assumed monotonicity, our
tests reject it. Therefore, our methods can be used in a broader scope of applications and are more
credible when monotonicity fails.
6.4. Evaluation of principal surrogate in the ACCTs data
According to the discussion in Section 5 about model checking, we believe that the model without
monotonicity is more credible, and thus all our discussion below is based on the results in Section
6.2 from the model without monotonicity.
In Section 6.2, we obtain that the posterior medians of ACEss and ACEs¯s¯ are very close to
zero, and both of their 95% credible intervals cover zero, which means that the candidate surro-
gate satisfies the causal necessity very well. Therefore, our analysis verifies the causal necessity
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(c) Posterior distributions of the principal strata without monotonicity.
Fig. 2. The solid lines are the posterior medians, and the dotted lines are the posterior 2.5% and 97.5%
quantiles.
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assumption in Baker et al. (2012). In addition, the posterior medians of ACEss¯ and ACEs¯s are
0.772 and −0.748, respectively, with both of their 95% credible intervals excluding zero, show-
ing that the surrogate also satisfies the causal sufficiency very well. We then have approximately
ACEss = 0, ACEs¯s¯ = 0, ACEss¯ > 0, and ACEss¯ +ACEs¯s ≥ 0. Thus, according to Corollary 1(ii),
the surrogate paradox can be avoided by using this surrogate, i.e., if the treatment has a positive
causal effect on the surrogate, it must have a positive causal effect on the endpoint. In fact, the
treatment has a positive average causal effect on the surrogate (posterior medians of ACESr are
greater than 0.015 in all trials), and we can conclude that it has a positive average causal effect on
the endpoint.
7. Sensitivity analysis without homogeneity
The homogeneity assumption is crucial for the identifiability of PSACEs. It may be violated if
different trials with different environments may affect the endpoint. Instead of assuming that δzur
does not depend on r, we propose a Bayesian hierarchical model to account for the heterogeneity
among δzur for different trials. We keep the conditional distributions of P (R), P (Z | R) and
P (U | R) unchanged, but assume the following hierarchical model for P (Y | Z,U,R):
Y | Z = z, U = u,R = r ∼ Bernoulli(δzur),
logit(δzur) ∼ N(µzu, σ2).
In this model, deviation from the homogeneity assumption is characterized by the sensitivity pa-
rameter σ. When σ = 0, δzur = δzu and thus the homogeneity assumption holds. When σ > 0, the
homogeneity assumption is violated. For example, when µzu = logit(0.3) and σ = 0.5, the parame-
ter δzur falls in the interval (0.139, 0.533) with probability 0.95; when µzu = logit(0.5) and σ = 0.5,
the parameter δzur falls in the interval (0.273, 0.727) with probability 0.95. Since the parameter
δzur is within the interval [0, 1], the above intervals imply quite large deviations away from the
homogeneity assumption. Therefore, we choose 0.5 as the maximum value of the sensitivity param-
eter σ, and choose 0.05 and 0.2 as two moderate values of σ. In our Bayesian analysis, we choose
the following priors: {P (Z = 1 | R = r) : r = 1, . . . , NR} ∼ Dirichlet(1, · · · , 1), P (Z = 1 | R = r)
∼ U(0, 1), {piss,r, piss¯,r, pis¯s¯,r, pis¯s,r} ∼ Dirichlet(1, · · · , 1), and µzu ∼ U(−5, 5). We use the prior of
µzu for numerical stability, and also [logit
(−1)(−5), logit(−1)(5)] = [0.007, 0.993] ≈ [0, 1] is not very
restrictive. The details of the Gibbs Sampler for the Bayesian hierarchical model are given in the
online Appendix.
We reanalyze the ACCTs data using the Bayesian hierarchical models with results shown in
Figure 3. Four rows correspond to the four principal strata (U = ss, ss¯, s¯s, s¯s¯), and three columns
correspond to the three values of σ (σ = 0.05, 0.2, 0.5). For each subgraph, we draw the 2.5%,
50% and 97.5% posterior quantiles of PSACEs obtained from both the homogeneity model and
Bayesian hierarchical models. The posterior distributions of PSACEs are robust for these different
values of the sensitivity parameter σ, although the intervals become wider as σ increases. The signs
of ACEss¯ and ACEs¯s remain positive and negative respectively, and the intervals of ACEss and
ACEs¯s¯ still cover zero. The results obtained by Bayesian hierarchical models remain unchanged by
removing the homogeneity assumption, which show the robustness of our results in Section 6.
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Fig. 3. Sensitivity analysis for the ACCTs data. The rows correspond to the four principal strata and the
columns correspond to the three different values of σ. The dashed lines are the posterior 2.5%, 50% and
97.5% quantiles from Bayesian hierarchical models, and the solid grey lines are the posterior quantiles from
the homogeneity model.
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8. Discussion
According to Frangakis and Rubin (2002), evaluation of surrogates requires identification of the
causal effects within principal strata. Because the potential outcomes of the surrogate endpoints
under treatment and control cannot be jointly observed, the value of the principal stratification
variable is missing. The monotonicity assumption excludes all the individuals with surrogate nega-
tively affected by the treatment, which may not be biologically reasonable. The exclusion restriction
assumption cannot be made when evaluating surrogates, because it implies the causal necessity and
the validity of the causal necessity is a scientific question of interest. Unfortunately, the identi-
fiability of the PSACEs are jeopardized without monotonicity or exclusion restriction. Although
Bayesian analysis for weakly identified models still yields proper posterior distributions under proper
priors, it may result in sensitive answers to the prior specification.
The ACCTs data contain multiple independent trials for evaluating the same surrogate for
the same endpoint. If we could make the homogeneity assumption across multiple trials, we can
remove the monotonicity and exclusion restriction assumptions but still guarantee identifiability
of the PSACEs. We find in the ACCTs data that both the “causal necessity” and the “causal
sufficiency” hold, which imply that the DFS with three-year follow-up is a valid surrogate for OS
with five-year follow-up. We investigate the applicability of the principal surrogate in new trials
on new populations or with new treatments, and show that the surrogate in the ACCTs data
could be a useful surrogate under some conditions. To remove the homogeneity assumption, we
further propose an approach based on Bayesian hierarchical models, and investigate the sensitivity
to the deviations from the homogeneity assumption. Within a reasonable range of the sensitivity
parameter, the conclusions for the ACCTs data remain stable.
The framework we proposed could be applied to various settings involving post-treatment inter-
mediate variables where the monotonicity and exclusion restriction assumptions are questionable.
For example, in randomized experiments with non-compliance, the assignment of the treatment
may influence the outcome directly. In these cases, we should concern the plausibility of exclusion
restriction assumptions versus the plausibility of homogeneity assumptions. Models with the homo-
geneity assumption may sometimes be more flexible in practice. With the homogeneity assumption,
we can test the monotonicity assumption. Furthermore, even if the homogeneity assumption does
not hold, we can still conduct a sensitivity analysis as in Section 7.
Follmann (2006), Qin et al. (2008) and Mattei and Mealli (2011) proposed augmented designs
for single trials to identify principal stratification causal effects using additional variables. From the
perspective of experimental design, our approach can be viewed as an extension of Follmann (2006),
which imposes a stronger monotonicity assumption for the treatment effect on the intermediate
variable. In our approaches, the number of trials R can be more general, as long as it satisfies the
assumptions for identification. We can design experiments to create a variable R, satisfying these
assumptions in order to identify the PSACEs. For example, in an encouragement experiment that
encourages the patients to take their assignments, we can use different types of encouragement for
different groups of people. Thus different groups will have different compliance behaviors, and the
indicator for encouragement types then acts like R in our paper.
Several generalizations are possible. First, it is relatively easy to deal with a continuous endpoint
because we can identify the distributional causal effect by dichotomizing the endpoint (Ding et al.,
2011). However, it is non-trivial to deal with a continuous surrogate endpoint since the causal
necessity and sufficiency cannot be defined by dichotomizing it. Schwartz et al. (2011) set the stage
for analyzing principal strata effects with continuous intermediate variables using a semiparametric
Bayesian approach. Second, we discuss the methods and present an application without missing
data, and dealing with the missing data problem will be of interest in many real applications.
Finally, generalizing our approaches to longitudinal data and time-to-event data is also of theoretical
and practical interest.
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Supplementary Materials
Appendix A derives the bounds for the PSACEs both with and without monotonicity, and shows the
application of these bounds to the ACCTs data. Appendix B provides the proofs for the propositions
and theorems. Appendix C gives the computational details. Appendix D provides more details about the
simulation studies.
We re-introduce all the notation used in the main text as follows:
Pzsr = P (S = s | Z = z,R = r), Qzsr = P (Y = 1 | Z = z, S = s,R = r),
ωys|zr = P (Y = y, S = s | Z = z,R = r), pr = P (R = r),
αr = P (Z = 1 | R = r), piur = P (U = u | R = r),
δzur = P (Y = 1 | Z = z, U = u,R = r), ACEur = E{Y (1)− Y (0) | U = u,R = r}.
Under the homogeneity assumption, we have:
δzu = P (Y = 1 | Z = z, U = u) = δzur, ACEu = E{Y (1)− Y (0) | U = u} = ACEur.
We further define p = {pr : r = 1, . . . , NR}, α = {αr : r = 1, . . . , NR}, pir = {piss,r, piss¯,r, pis¯s¯,r, pis¯s,r},
pi = {pir : r = 1, . . . , NR}, and δ = {δzu : z = 0, 1;u = ss, ss¯, s¯s¯, s¯s}.
Appendix A: Bounds for PSACEs
We need the following lemma to simplify the derivations of the bounds.
Lemma 1. Let X0 be a mixture of two Bernoulli distributions X1 and X2 with X0 ∼ αX1 + (1 −
α)X2, Xi ∼ Bernoulli(pi), and a known mixing proportion α. Then we have
max
(
0, 1− 1− p0
α
)
≤ p1 ≤ min
(
1,
p0
α
)
,
max
(
0, 1− 1− p0
1− α
)
≤ p2 ≤ min
(
1,
p0
1− α
)
.
Proof of Lemma 1. See Cheng and Small (2006). 2
Appendix A.1: Bounds without monotonicity
Let Uppernm(ACEur) and Lowernm(ACEur) denote the upper and lower bounds of ACEur without mono-
tonicity, respectively.
Proposition A.4. Without monotonicity, the bounds of ACEss,r are
Uppernm(ACEss,r) = min
{
1,
Q11rP11r
P01r − P10r
}
+ min
{
0,
(1−Q01r)P01r
P01r − P10r − 1
}
,
Lowernm(ACEss,r) = max
{
0, 1− (1−Q11r)P11r
P01r − P10r
}
−min
{
1,
Q01rP01
P01r − P10r
}
,
if P01r ≥ P10r, and [−1, 1] if P01r < P10r. The bounds of ACEss¯,r are
Uppernm(ACEss¯,r) = min
{
1,
Q11rP11r
P11r − P01r
}
−max
{
0,
Q00rP00r − P10r
P11r − P01r
}
,
Lowernm(ACEss¯,r) = max
{
0,
Q11rP11r
P11r − P01r − 1
}
−min
{
1,
Q00rP00r
P11r − P01r
}
,
if P01r ≤ P11r, and [−1, 1] if P01r > P11r. The bounds of ACEs¯s¯,r are:
Uppernm(ACEs¯s¯,r) = min
{
1,
Q10rP10r
P10r − P01r
}
−max
{
0,
Q00rP00r − P11r
P10r − P01r
}
,
Lowernm(ACEs¯s¯,r) = max
{
0,
Q10rP10r − P01r
P10r − P01r
}
−min
{
1,
Q00rP00r
P10r − P01r
}
,
if P01r ≤ P10r, and [−1, 1] if P01r > P10r. The bounds of ACEs¯s,r are:
Uppernm(ACEs¯s,r) = min
{
1,
Q10rP10r
P01r − P11r
}
−max
{
0,
Q01rP01r − P11r
P01r − P11r
}
,
Lowernm(ACEs¯s,r) = max
{
0,
Q10rP10r − P00r
P01r − P11r
}
−min
{
1,
Q01rP01r
P01r − P11r
}
,
if P01r ≥ P11r, and [−1, 1] if P01r < P11r.
Proof of Proposition A.4. Without monotonicity, each of the subpopulation with (Z = z, S = s) is a mixture
of two latent principal strata, implying that
pis¯s¯,r + piss¯,r = P00r, (A.4)
piss,r + pis¯s,r = P01r, (A.5)
pis¯s¯,r + pis¯s,r = P10r, (A.6)
piss,r + piss¯,r = P11r, (A.7)
piss,r + piss¯,r + pis¯s¯,r + pis¯s,r = 1, (A.8)
δ1,ss,r
piss,r
P11r
+ δ1,ss¯,r
piss¯,r
P11r
= Q11r, (A.9)
δ0,ss,r
piss,r
P01r
+ δ0,s¯s,r
pis¯s,r
P01r
= Q01r. (A.10)
Supposing that we know pis¯s,r in Equations (A.4) and (A.8), we can express piur’s in terms of pis¯s,r :
piss,r = P01r − pis¯s,r, (A.11)
pis¯s¯,r = P10r − pis¯s,r, (A.12)
piss¯,r = 1− (piss,r + pis¯s¯,r + pis¯s,r) = P11r − P01r + pis¯s,r. (A.13)
Since 0 ≤ piur ≤ 1, we can obtain the bounds for pis¯s,r from Equations (A.11) to (A.13):
pis¯s,r ∈ [max(0, P01r − P11r),min(P01r, P10r)] ≡ Rr.
From Lemma 1 and Equations (A.9) and (A.10), we can get the bounds of ACEss,r for a given pis¯s,r:
Uppernm(ACEss,r | pis¯s,r)
= min
{
1,
Q11rP11r
P01r − pis¯s,r
}
−max
{
0,
Q01rP01r − pis¯s,r
P01r − pis¯s,r
}
= min
{
1,
Q11rP11r
P01r − pis¯s,r
}
+ min
{
0,
(1−Q01r)P01r
P01r − pis¯s,r − 1
}
,
Lowernm(ACEss,r | pis¯s,r)
= max
{
0,
Q11rP11r − P11r + P01r − pis¯s,r
P01r − pis¯s,r
}
−min
{
1,
Q01rP01r
P01r − pis¯s,r
}
= max
{
0, 1− (1−Q11r)P11r
P01r − pis¯s,r
}
−min
{
1,
Q01rP01r
P01r − pis¯s,r
}
.
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The bounds for ACEss,r can be obtained by maximizing or minimizing the above bounds over Rr, the
feasible region of pis¯s,r, namely,
Uppernm(ACEss,r)
= max
pis¯s,r∈Rr
[
min
{
1,
Q11rP11r
P01r − pis¯s,r
}
+ min
{
0,
(1−Q01r)P01r
P01r − pis¯s,r − 1
}]
,
Lowernm(ACEss,r)
= min
pis¯s,r∈Rr
[
max
{
0, 1− (1−Q11r)P11r
P01r − pis¯s,r
}
−min
{
1,
Q01rP01r
P01r − pis¯s,r
}]
.
Since
min
{
1,
Q11rP11r
P01r − pis¯s,r
}
+ min
{
0,
(1−Q01r)P01r
P01r − pis¯s,r − 1
}
is increasing in pis¯s,r, and
max
{
0, 1− (1−Q11r)P11r
P01r − pis¯s,r
}
−min
{
1,
Q01rP01r
P01r − pis¯s,r
}
is decreasing in pis¯s,r, the above bounds can be simplified as
Uppernm(ACEss,r) = min
{
1,
Q11rP11r
P01r − P10r
}
+ min
{
0,
(1−Q01r)P01r
P01r − P10r − 1
}
,
Lowernm(ACEss,r) = max
{
0, 1− (1−Q11r)P11r
P01r − P10r
}
−min
{
1,
Q01rP01
P01r − P10r
}
,
if P01r ≥ P10r, and [−1, 1] if P01r < P10r.
Similarly, we can obtain the bounds of the other three principal strata. 2
Appendix A.2: Bounds with monotonicity
Let Upperm(ACEur) and Lowerm(ACEur) denote the upper and lower bounds of ACEur without mono-
tonicity, respectively.
Proposition A.2. With monotonicity, the bounds of ACEss,r are
Upperm(ACEss,r) = min
{
1,
Q11rP11r
P01r
}
−Q01r,
Lowerm(ACEss,r) = max
{
0,
Q11rP11r − P11r + P01r
P01r
}
−Q01r;
the bounds for ACEss¯,r are
Upperm(ACEss¯,r) = min
{
1,
Q11rP11r
P11r − P01r
}
−max
{
0,
Q00rP00r − P10r
P11r − P01r
}
,
Lowerm(ACEss¯,r) = max
{
0,
Q11rP11 − P10r
P01r
}
−min
{
1,
Q00rP00r
P11 − P01r
}
;
and the bounds for ACEss,r are
Upperm(ACEs¯s¯,r) = Q10r −max
{
0,
Q00rP00r − P11r + P10r
P10r
}
,
Lowerm(ACEs¯s¯,r) = Q10r −min
{
1,
Q00rP00r
P10r
}
.
Proof of Proposition A.2. When monotonicity holds, we have pis¯s,r = 0, and we can identify the proportions
of all the principal strata, and thus we have
Upperm(ACEss,r) = Uppernm(ACEss,r | pis¯s,r = 0),
Lowerm(ACEss,r) = Lowernm(ACEss,r | pis¯s,r = 0).
Similarly, we can obtain the bounds of the other two principal strata. 2
Appendix A.3: Bounds for the ACCTs data
We compute bounds of the PSACEs for the 10 trials separately. Figure 5 shows the large sample bounds and
confidence intervals for PSACEs based on the bootstrap (Cheng and Small, 2006). Figure 5(b) shows that,
without monotonicity, bounds of the PSACEs are barely informative. These bounds always contain zero,
and bounds of ACEs¯s¯,r and ACEs¯s,r are [−1, 1], which are too wide for us to get any useful information.
Figure 5(a) shows that, with monotonicity, bounds are sometimes informative. But the confidence intervals
for the PSACEs always contain zero, which do not provide strong evidence for the presence of causal effects.
Standard resampling techniques, including the bootstrap, may be inconsistent and lead to confidence
sets that are not asymptotically valid in a point-wise or uniform sense for drawing inference on partially
identified quantities (Andrews, 2000; Andrews and Guggenberger, 2009; Romano and Shaikh, 2010). Here
we follow Cheng and Small (2006)’s procedure to obtain the confidence intervals for the bounds, which is
easy to implement. For more careful analysis, we can use the methods developed by Chernozhukov et al.
(2013). However, we do not do this here because calculating the bounds is not our primary goal. And what
is more, the bounds are barely informative in our application.
Appendix B: Proofs of the propositions and theorems
Appendix B.1: Proof of Proposition 1 in Section 3
Proposition 1. Under Assumption 1, Assumption 3 is equivalent to R Y | (U,Z), which implies
ACEur = ACEur′ for all u = ss, ss¯, s¯s, s¯s¯ and r 6= r′.
Proof of Proposition 1. Under randomization and homogeneity (Assumption 3), we have
P (Y = 1 | U = u,R = r, Z = z)
= P{Y (z) = 1 | U = u,R = r, Z = z}
= P{Y (z) = 1 | U = u,R = r} = P{Y (z) = 1 | U = u},
and
P (Y = 1 | U = u, Z = z)
=
∑
r
P (Y = 1 | U = u,R = r, Z = z) · P (R = r | U = u, Z = z)
=
∑
r
P{Y (z) = 1 | U = u} · P (R = r | U = u, Z = z)
= P{Y (z) = 1 | U = u} ·
∑
r
P (R = r | U = u, Z = z)
= P{Y (z) = 1 | U = u} = P (Y = 1 | U = u,R = r, Z = z),
implying R Y | (U,Z). Thus we have
P (Y = 1 | U = u,R = r, Z = z) = P (Y = 1 | U = u,R = r′, Z = z)
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for z = 0, 1; u = ss, ss¯, s¯s, s¯s¯; and r, r′ = 1, . . . , NR. Under homogeneity (Assumption 3), we have E{Y (z) |
U = u,R = r} = E{Y (z) | U = u}, and thus ACEur = ACEur′ , for z = 0, 1; u = ss, ss¯, s¯s, s¯s¯; and
r, r′ = 1, . . . , NR. In addition, under randomization and homogeneity (Assumption 3), we have
P{Y (z) | U = u,R = r} = P (Y | Z = z, U = u,R = r) = P (Y | Z = z, U = u),
and thus ACEu = δ1u − δ0u does not depend on r. 2
Appendix B.2: Proof of Theorem 1 in Section 3.1
Theorem 2. Under Assumptions 1 to 4, we have that, for u = ss, ss¯ and s¯s¯,
(a) P (Y = 1 | Z = 1, U = u) for all principal strata u are identifiable if Assumption 4(a) holds;
(b) P (Y = 1 | Z = 0, U = u) for all principal strata u are identifiable if Assumption 4(b) holds;
(c) ACEu for all principal strata u are identifiable if both Assumptions 4(a) and 4(b) hold.
Proof of Theorem 2. First, we can identify the proportions of all the principal strata under monotonicity.
Let ωys|zr = P (Y = y, S = s | Z = z,R = r) denote the probability of (Y = y, S = s) given (Z = z,R = r),
which can be identified from the observed data.
The subpopulation with (Z = 1, S = 0) is equivalent to stratum s¯s¯ under treatment, and the subpopu-
lation with (Z = 0, S = 1) is equivalent to stratum ss under control. Homogeneity (Assumption 3) implies
that ω10|1r = δ1,s¯s¯ · pis¯s¯,r and ω11|0r = δ0,ss · piss,r, and therefore we can identify δ1,s¯s¯ = ω10|1r/pis¯s¯,r and
δ0,ss = ω11|0r/piss,r from the observed data directly.
The subpopulation with (Z = 1, S = 1) is a mixture of two latent strata ss and ss¯, and under homo-
geneity (Assumption 3) we have:
ω11|1r = δ1,ss · piss,r + δ1,ss¯ · piss¯,r.
For the two trials r1 and r2 satisfying Assumption 4(a) with piss,r1piss¯,r2 6= piss¯,r1piss,r2 , we have:{
ω11|1r1 = δ1,ss · piss,r1 + δ1,ss¯ · piss¯,r1 ,
ω11|1r2 = δ1,ss · piss,r2 + δ1,ss¯ · piss¯,r2 ,
from which we can find a unique solution for (δ1,ss, δ1,ss¯): δ1,ss =
piss¯,r2ω11|1r1−piss¯,r1ω11|1r2
piss,r1piss¯,r2−piss¯,r1piss,r2
,
δ1,ss¯ =
piss,r1ω11|1r2−piss,r2ω11|1r1
piss,r1piss¯,r2−piss¯,r1piss,r2
.
Similarly, the subpopulation with (Z = 0, S = 0) is a mixture of two latent strata ss¯ and s¯s¯, and under
homogeneity (Assumption 3) we have:
ω10|0r = δ0,s¯s¯ · pis¯s¯,r + δ0,ss¯ · piss¯,r.
For the two trials r3 and r4 satisfying Assumption 4(b) with pis¯s¯,r3piss¯,r4 6= piss¯,r3pis¯s¯,r4 , we have:{
ω10|0r3 = δ0,s¯s¯ · pis¯s¯,r3 + δ0,ss¯ · piss¯,r3 ,
ω10|0r4 = δ0,s¯s¯ · pis¯s¯,r4 + δ0,ss¯ · piss¯,r4 ,
from which we can obtain a unique solution to (δ0,s¯s¯, δ0,ss¯): δ0,s¯s¯ =
piss¯,r4ω10|0r3−piss¯,r3ω10|0r4
pis¯s¯,r3piss¯,r4−piss¯,r3pis¯s¯,r4
,
δ0,ss¯ =
pis¯s¯,r3ω10|0r4−pis¯s¯,r4ω10|0r3
pis¯s¯,r3piss¯,r4−piss¯,r3pis¯s¯,r4
.
Since ACEu = δ1u − δ0u, we can identify ACEu’s under Assumptions 1 to 4. 2
Table B.3.2. True values of P (Z = 1 | R = r)
and P (U = u | R = r)
r = 1 r = 2 r = 3
P (Z = 1 | R = r) 0.4 0.5 0.6
piss,r 0.6 0.1 0.1
piss¯,r 0.2 0.6 0.1
pis¯s¯,r 0.1 0.2 0.6
pis¯s,r 0.1 0.1 0.2
Appendix B.3: Proof of Proposition 2 in Section 3.2
Proposition 2. Under Assumptions 1 and 3, a necessary condition for the local identifiability of the
joint distribution of (Y,Z, S, U,R) is NR ≥ 3.
Proof of Proposition 2. The observed data of (R,Z, S, Y ) form an NR × 2 × 2 × 2 contingency table
with (8NR − 1) free frequencies, therefore the saturated model contains (8NR − 1) parameters. The joint
distributions contains (5NR + 7) parameters, with P (R) contributing (NR − 1) parameters, P (Z | R)
contributing NR parameters, P (U | R) contributing 3NR parameters, and P (Y | Z,U) contributing 8
parameters. Therefore, the model with monotonicity has (8NR − 1) − (5NR + 7) = (3NR − 8) degrees of
freedom, which is positive when NR ≥ 3.
Example B.3.5. Suppose we have three trials. We set true parameters as
(δ1,ss, δ0,ss, δ1,ss¯, δ0,ss¯, δ1,s¯s¯, δ0,s¯s¯, δ1,s¯s, δ0,s¯s) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2),
and display other parameters in Table B.3.1.
We can then get the observed distribution of P (Z = z, S = s, Y = y | R = r) as shown in Table B.3.2.
By the homogeneity assumption, the probabilities of the observed data can be decomposed as
P (Z = z, S = s, Y = y | R = r)
=
∑
u∈O(z,s)
P (Z = z | R = r) · piur · P (Y = y | Z = z, U = u), (B.1)
for z, s, y = 0, 1. Similar to the proof of Proposition 2, we can obtain that the number of parameters on the
right-hand side of Equation (B.1) is 20. The observed distribution of (Z, S, Y | R) form a contingency table
with 21 free frequencies on the left-hand side of Equation (B.1). We can use R package neqslv to solve these
equations. We obtain that
(δ1,ss, δ0,ss, δ1,ss¯, δ0,ss¯, δ1,s¯s¯, δ0,s¯s¯, δ1,s¯s, δ0,s¯s) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2),
which are the same as the true parameters.
Appendix B.4: Proof of Proposition 3 in Section 4
Proposition 3. For trial r, assume that the principal surrogate satisfies the causal necessity.
(i) With monotonicity, we have ACEYr = ACE
S
r ×ACEss¯,r.
(ii) Without monotonicity, suppose ACESr > 0, we have that, if ACEss¯,r +ACEs¯s,r ≥ 0,
ACESr ×ACEss¯,r ≤ ACEYr ≤ (ACEss¯,r +ACEs¯s,r)/2 +ACESr × (ACEss¯,r −ACEs¯s,r)/2,
and otherwise
(ACEss¯,r +ACEs¯s,r)/2 +ACE
S
r × (ACEss¯,r −ACEs¯s,r)/2 ≤ ACEYr ≤ ACESr ×ACEss¯,r.
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Table B.3.3. Observed distribution of P (Z = z, S = s, Y = y | R = r)
R = 1 R = 2 R = 3
Z = 1 Z = 0 Z = 1 Z = 0 Z = 1 Z = 0
S = 1, Y = 1 0.248 0.192 0.250 0.035 0.090 0.036
S = 1, Y = 0 0.072 0.228 0.100 0.065 0.030 0.084
S = 0, Y = 1 0.044 0.042 0.085 0.100 0.276 0.036
S = 0, Y = 0 0.036 0.138 0.065 0.300 0.204 0.244
Proof: With monotonicity, from the causal necessity ACEss,r = ACEs¯s¯,r = 0, we have
ACEYr = E{Y (1)− Y (0) | R = r} = E{Y (1)− Y (0) | U = ss¯, R = r}piss¯,r = ACEss¯,rpiss¯,r.
Monotonicity also implies that ACESr = E{S(1)− S(0) | R = r} = piss¯,r, and therefore ACEYr = ACESr ×
ACEss¯,r.
Without monotonicity, from the causal necessity, we have
ACEYr =
∑
u
E{Y (1)− Y (0) | U = u,R = r}piur = ACEss¯,rpiss¯,r +ACEs¯s,rpis¯s,r.
Since piss¯,r − pis¯s,r = E{S(1)− S(0) | R = r} = ACESr , the above equation can be rearranged as
ACEYr = (ACEss¯,r +ACEs¯s,r)pis¯s,r +ACE
S
r ×ACEss¯,r.
From the linear constraints 0 ≤ pis¯s,r, piss¯,r ≤ 1, pis¯s,r + piss¯,r ≤ 1 and piss¯,r − pis¯s,r = ACESr , we obtain
pis¯s,r ∈ [max(0,−ACESr ), (1−ACESr )/2] = [0, (1−ACESr )/2]. If ACEss¯,r +ACEs¯s,r ≥ 0, we have
ACESr ×ACEss¯,r ≤ ACEYr
≤ (ACEss¯,r +ACEs¯s,r)× (1−ACESr )/2 +ACESr ×ACEss¯,r
= (ACEss¯,r +ACEs¯s,r)/2 +ACE
S
r × (ACEss¯,r −ACEs¯s,r)/2.
Otherwise, we have
(ACEss¯,r +ACEs¯s,r)/2 +ACE
S
r × (ACEss¯,r −ACEs¯s,r)/2 ≤ ACEYr ≤ ACESr ×ACEss¯,r.
Appendix C: EM algorithms and the Gibbs Samplers
Let Ntotal denote the total sample size. Let nzuyr be the frequencies of the complete data, i.e., the
frequencies of patients with (Z = z, U = u, Y = y,R = r), for z = 0, 1; r = 1, . . . , NR; y = 0, 1; and
u = ss, ss¯, s¯s¯, s¯s. Let Nzsyr be the frequencies of the observed data, i.e., the frequencies of patients with
(Z = z, S = s, Y = y,R = r), for z = 0, 1; r = 1, . . . , NR; y = 0, 1; and s = 0, 1.
Appendix C.1: EM algorithm with monotonicity
We can write the complete-data likelihood as
Lc(ξ) ∝
NR∏
r=1
(
p
n+++r
r · αn1++rr (1− αr)n0++r ·
∏
u=ss,ss¯,s¯s¯
pi
n+u+r
ur
)
·
∏
z,u
δ
nzu1+
zu (1− δzu)nzu0+ ·
Ntotal∏
i=1
I{Ui ∈ O(Zi, Si)}, (C.1)
where I{·} is the indicator function. Let ξ(k) be the estimate of ξ after the k-th iteration.
In the E-step, we need to calculate n
(k+1)
zuyr = E(nzuyr | Nzsyr, ξ(k)) given the observed data and ξ(k).
Under monotonicity, it is relatively straightforward to obtain that n
(k+1)
0,ss,y,r = N01yr and n
(k+1)
1,s¯s¯,y,r = N10yr.
For other frequencies, we have
n
(k+1)
1,ss,1,r = N111r
pi
(k)
ss,rδ
(k)
1,ss
pi
(k)
ss,rδ
(k)
1,ss+pi
(k)
ss¯,rδ
(k)
1,ss¯
, n
(k+1)
1,ss¯,1,r = N111r − n(k+1)1,ss,1,r,
n
(k+1)
1,ss,0,r = N110r
pi
(k)
ss,r(1−δ(k)1,ss)
pi
(k)
ss,r(1−δ(k)1,ss)+pi
(k)
ss¯,r(1−δ
(k)
1,ss¯)
, n
(k+1)
1,ss¯,0,r = N110r − n(k+1)1,ss,0,r,
n
(k+1)
0,s¯s¯,1,r = N001r
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯+pi
(k)
ss¯,rδ
(k)
1,ss¯
, n
(k+1)
0,s¯s,1,r = N001r − n(k+1)0,s¯s¯,1,r,
n
(k+1)
0,s¯s¯,0,r = N000r
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)+pi
(k)
ss¯,r(1−δ
(k)
1,ss¯)
, n
(k+1)
0,s¯s,0,r = N000r − n(k+1)0,s¯s¯,0,r.
In the M-step, we update the parameters as follows:
p(k+1)r =
n
(k+1)
+++r
n
(k+1)
++++
, α(k+1)r =
n
(k+1)
1++r
n
(k+1)
+++r
, pi(k+1)ur =
n
(k+1)
+u+r
n
(k+1)
+++r
, δ(k+1)zu =
n
(k+1)
zu1+
n
(k+1)
zu++
.
Appendix C.2: EM algorithm without monotonicity
We can write the complete-data likelihood as
Lc(ξ) ∝
NR∏
r=1
(
p
n+++r
r · αn1++rr (1− αr)n0++r ·
∏
u=ss,ss¯,s¯s¯,s¯s
pi
n+u+r
ur
)
·
∏
z,u
δ
nzu1+
zu (1− δzu)nzu0+ ·
Ntotal∏
i=1
I{Ui ∈ O(Zi, Si)}, (C.2)
In the E-step, we need to calculate n
(k+1)
zuyr = E(nzuyr | Nzsyr, ξ(k)) given the observed data and ξ(k) as
follows:
n
(k+1)
1,ss,1,r = N111r
pi
(k)
ss,rδ
(k)
1,ss
pi
(k)
ss,rδ
(k)
,1ss+pi
(k)
ss¯,rδ
(k)
1,ss¯
, n
(k+1)
1,ss¯,1,r = N111r − n(k+1)1,ss,1,r,
n
(k+1)
1,ss,0,r = N110r
pi
(k)
ss,r(1−δ(k)1,ss)
pi
(k)
ss,r(1−δ(k)1,ss)+pi
(k)
ss¯,r(1−δ
(k)
1,ss¯)
, n
(k+1)
1,ss¯,0,r = N110r − n(k+1)1,ss,0,r,
n
(k+1)
1,s¯s¯,1,r = N101r
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯+pi
(k)
s¯s,rδ
(k)
1,s¯s
, n
(k+1)
1,s¯s,1,r = N101r − n(k+1)1,s¯s¯,1,r,
n
(k+1)
1,s¯s¯,0,r = N100r
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)+pi
(k)
s¯s,r(1−δ
(k)
1,s¯s)
, n
(k+1)
1,s¯s,0,r = N100r − n(k+1)1,s¯s¯,0,r,
n
(k+1)
0,ss,1,r = N011r
pi
(k)
ss,rδ
(k)
1,ss
pi
(k)
ss,rδ
(k)
1,ss+pi
(k)
s¯s,rδ
(k)
1,s¯s
, n
(k+1)
0,s¯s,1,r = N011r − n(k+1)0,ss,1,r,
n
(k+1)
0,ss,0,r = N010r
pi
(k)
ss,r(1−δ(k)1,ss)
pi
(k)
ss,r(1−δ(k)1,ss)+pi
(k)
s¯s,r(1−δ
(k)
1,s¯s)
, n
(k+1)
0,s¯s,0,r = N010r − n(k+1)0,ss,0,r,
n
(k+1)
0,s¯s¯,1,r = N001r
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯
pi
(k)
s¯s¯,rδ
(k)
1,s¯s¯+pi
(k)
ss¯,rδ
(k)
1,ss¯
, n
(k+1)
0,s¯s,1,r = N001r − n(k+1)0,s¯s¯,1,r,
n
(k+1)
0,s¯s¯,0,r = N000r
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)
pi
(k)
s¯s¯,r(1−δ
(k)
1,s¯s¯)+pi
(k)
ss¯,r(1−δ
(k)
1,ss¯)
, n
(k+1)
0,s¯s,0,r = N000r − n(k+1)0,s¯s¯,0,r.
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In the M-step, we can update the parameters as follows:
p(k+1)r =
n
(k+1)
+++r
n
(k+1)
++++
, α(k+1)r =
n
(k+1)
1++r
n
(k+1)
+++r
, pi(k+1)ur =
n
(k+1)
+u+r
n
(k+1)
+++r
, δ(k+1)zu =
n
(k+1)
zu1+
n
(k+1)
zu++
.
Appendix C.3: Gibbs Sampler with monotonicity
We treat U as the missing data, and the Gibbs sampler iterates between the following imputation and
posterior steps. In the imputation step, we draw U given the observed data and all the parameters. When
(Zi = 1, Si = 0), we impute Ui = s¯s¯; when (Zi = 0, Si = 1), we impute Ui = ss; when (Zi = 1, Si = 1), we
impute Ui as:
P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ) =
δYi1,ss¯(1− δ1,ss¯)1−Yipiss¯,Ri∑
u=ss,ss¯ δ
Yi
1,u(1− δ1,u)1−Yipiu,Ri
,
P (Ui = ss | Zi = 1, Si = 1, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ);
when (Zi = 0, Si = 0), we impute Ui as:
P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ) =
δYi0,ss¯(1− δ0,ss¯)1−Yipiss¯,Ri∑
u=s¯s¯,ss¯ δ
Yi
0,u(1− δ0,u)1−Yipiu,Ri
,
P (Ui = s¯s¯ | Zi = 0, Si = 0, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ).
After imputing U , we can compute the frequencies of the complete data.
In the posterior step, we draw all the parameters given the complete data. Specifically, we draw the
parameters from the following conditional distributions:
(p1, p2, · · · , pNR) | · ∼ Dirichlet(n+++1 + 1, · · · , n+++NR + 1),
αr | · ∼ Beta(n1++r + 1, n0++r + 1), ∀r,
(piss,r, piss¯,r, pis¯s¯,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss¯+r + 1, n+s¯s¯+r + 1),
δzu | · ∼ Beta(nzu1+ + 1, nzu0+ + 1),∀u, z.
Appendix C.4: Gibbs Sampler without monotonicity
We treat U as the missing data, and the Gibbs sampler iterates between the following imputation and
posterior steps. In the imputation step, we draw U given the observed data and all the parameters. When
(Zi = 1, Si = 1), we impute Ui as:
P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ) =
δYi1,ss¯(1− δ1,ss¯)1−Yipiss¯,Ri∑
u=ss,ss¯ δ
Yi
1,u(1− δ1,u)1−Yipiu,Ri
,
P (Ui = ss | Zi = 1, Si = 1, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ);
when (Zi = 0, Si = 0), we impute Ui as:
P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ) =
δYi0,ss¯(1− δ0,ss¯)1−Yipiss¯,Ri∑
u=s¯s¯,ss¯ δ
Yi
0,u(1− δ0,u)1−Yipiu,Ri
,
P (Ui = s¯s¯ | Zi = 0, Si = 0, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ);
when (Zi = 1, Si = 0), we impute Ui as:
P (Ui = s¯s | Zi = 1, Si = 0, Ri, Yi, ξ) =
δYi1,s¯s(1− δ1,s¯s)1−Yipis¯s,Ri∑
u=s¯s,s¯s¯ δ
Yi
1,u(1− δ1,u)1−Yipiu,Ri
,
P (Ui = s¯s¯ | Zi = 1, Si = 0, Ri, Yi, ξ) = 1− P (Ui = s¯s | Zi = 1, Si = 0, Ri, Yi, ξ);
when (Zi = 0, Si = 1), we impute Ui as:
P (Ui = s¯s | Zi = 0, Si = 1, Ri, Yi, ξ) =
δYi0,s¯s(1− δ0,s¯s)1−Yipis¯s,Ri∑
u=s¯s,ss δ
Yi
0,u(1− δ0,u)1−Yipiu,Ri
,
P (Ui = ss | Zi = 0, Si = 1, Ri, Yi, ξ) = 1− P (Ui = s¯s | Zi = 0, Si = 1, Ri, Yi, ξ).
After imputing U , we can compute the frequencies of the complete data.
In the posterior step, we draw all the parameters given the complete data. Specifically, we draw the
parameters from the following conditional distributions:
(p1, p2, · · · , pNR) | · ∼ Dirichlet(n+++1 + 1, · · · , n+++NR + 1),
αr | · ∼ Beta(n1++r + 1, n0++r + 1),∀r,
(piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss¯+r + 1, n+s¯s¯+r + 1, n+s¯s+r + 1),
δzu | · ∼ Beta(nzu1+ + 1, nzu0+ + 1), ∀z, u.
Appendix C.5: Gibbs Sampler for the Bayesian hierarchical model in Section 7
Define ηzur = logit(δzur),η = {ηzur : z = 0, 1;u = ss, ss¯, s¯s, s¯s¯}, and θ = (ξ,η). The complete data
likelihood is
Lc(θ)
∝
NR∏
r=1
{
p
n+++r
r · αn1++rr (1− αr)n0++r
∏
u=ss,ss¯,s¯s¯,s¯s
pi
n+u+r
ur
}
·
∏
z,u,r
[
{logit−1(ηzur)}nzu1r{1− logit−1(ηzur)}nzu0r (σ2)−1/2 exp(− (ηzur − µzu)
2
2σ2
)
]
·
Ntotal∏
i=1
I{Ui ∈ O(Zi, Si)}.
We treat U as the missing data, and the Gibbs sampler iterates between the following imputation and
posterior steps. In the imputation step, we draw U given the observed data and all the parameters. When
(Zi = 1, Si = 1), we impute Ui as:
P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ) =
δYi1,ss¯,Ri(1− δ1,ss¯,Ri)1−Yipiss¯,Ri∑
u=ss,ss¯ δ
Yi
1,u,Ri
(1− δ1,u,Ri)1−Yipiu,Ri
,
P (Ui = ss | Zi = 1, Si = 1, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 1, Si = 1, Ri, Yi, ξ);
when (Zi = 0, Si = 0), we impute Ui as:
P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ) =
δYi0,ss¯,Ri(1− δ0,ss¯,Ri)1−Yipiss¯,Ri∑
u=s¯s¯,ss¯ δ
Yi
0,u,Ri
(1− δ0,u,Ri)1−Yipiu,Ri
,
P (Ui = s¯s¯ | Zi = 0, Si = 0, Ri, Yi, ξ) = 1− P (Ui = ss¯ | Zi = 0, Si = 0, Ri, Yi, ξ);
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when (Zi = 1, Si = 0), we impute Ui as:
P (Ui = s¯s | Zi = 1, Si = 0, Ri, Yi, ξ) =
δYi1,s¯s,Ri(1− δ1,s¯s,Ri)1−Yipis¯s,Ri∑
u=s¯s,s¯s¯ δ
Yi
1,u,Ri
(1− δ1,u,Ri)1−Yipiu,Ri
,
P (Ui = s¯s¯ | Zi = 1, Si = 0, Ri, Yi, ξ) = 1− P (Ui = s¯s | Zi = 1, Si = 0, Ri, Yi, ξ);
when (Zi = 0, Si = 1), we impute Ui as:
P (Ui = s¯s | Zi = 0, Si = 1, Ri, Yi, ξ) =
δYi0,s¯s,Ri(1− δ0,s¯s,Ri)1−Yipis¯s,Ri∑
u=s¯s,ss δ
Yi
0,u,Ri
(1− δ0,u,Ri)1−Yipiu,Ri
,
P (Ui = ss | Zi = 0, Si = 1, Ri, Yi, ξ) = 1− P (Ui = s¯s | Zi = 0, Si = 1, Ri, Yi, ξ).
After imputing U , we can compute the frequencies of the complete data.
In the posterior step, we draw all the parameters given the complete data. Specifically, we draw the
parameters from the following conditional distributions:
(p1, p2, · · · , pNR) | · ∼ Dirichlet(n+++1 + 1, · · · , n+++NR + 1),
αr | · ∼ Beta(n1++r + 1, n0++r + 1), ∀r,
(piss,r, piss¯,r, pis¯s¯,r, pis¯s,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss¯+r + 1, n+s¯s¯+r + 1, n+s¯s+r + 1),
µzu | · ∝ exp
{∑NR
r=1(ηzur − µzu)2
2σ2
}
· I(µzu ∈ [−5, 5]), ∀z, u,
p(ηzur | ·) ∝ {expit(ηzur)}nzu1r{1− expit(ηzur)}nzu0r
· exp
{
− (ηzur − µzu)
2
2σ2
}
∝ e
−nzu0r·ηzur− (ηzur−µzu)
2
2σ2
(1 + e−ηzur )nzu+r
, ∀z, u, r.
The first three conditional distributions are standard. The fourth one is a truncated Normal distribution,
which can be generated by applying the inverse of its cumulative distribution function to a Uniform(0, 1)
random variable. The posterior distribution of ηzur is not standard, but fortunately its conditional density
is log concave since
∂2 log{p(ηzur | ·)}
∂η2zur
= − 1
σ2
− nzu+re
−ηzur
(1 + e−ηzur )2
< 0.
Therefore its posterior distribution is unimodal, and we can use the Metropolized Independence Sampler
(Liu, 2001) to sample ηzur using a Normal proposal. We choose the proposal distribution as η ∼ N(η̂, ψ̂),
where η̂ is the mode of the posterior distribution and ψ̂ is the inverse of the Fisher information at the mode.
Due to the log concave density, we can simply use the Newton-Raphson iteration to find the mode η̂.
Appendix D: More details about the simulation studies
For the correctly specified model, Figures 6(a) and 6(b) show the results for ACEss¯, and Figures 7(a) and
7(b) show the results for ACEs¯s¯, with the biases and RMSEs of the MLEs and the coverage proportions
of the posterior credible intervals. For the misspecified models, Figures 6(c) and 6(d) show the results for
ACEss¯, Figures 7(c) and 7(d) show the results for ACEs¯s¯, and Figures 8(a) and 8(b) show the results for
ACEs¯s, with the biases and RMSEs of the MLEs and the coverage proportions of the posterior credible
intervals. The reason why the RMSEs with more trials may be larger for the same strata is that certain
settings of parameters may make the sample sizes smaller for the strata with more trials.
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Fig. 5. Bounds for the PSACEs with and without monotonicity. The solid lines are the bounds and the dotted
lines are the confidence intervals for the bounds.
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(a) Correctly specified model with monotonicity
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(b) Correctly specified model without monotonicity
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(c) Misspecified model with monotonicity
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(d) Misspecified model without monotonicity
Fig. 6. Simulations for homogeneity (a) and (b) and heterogeneity (c) and (d). Each subgraph presents the
bias, RMSE, coverage proportions of the 95% credible intervals of ACEss¯. Nine combinations of NR and N
are shown in (a) and (b); and nine combinations of N and d (“1” for .01, “2” for .025, “3” for .05) are shown in
(c) and (d).
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(a) Correctly specified model with monotonicity
l l
l
l l
l
l l
l
−
0.
10
0.
00
0.
05
0.
10
Bias
N=100 N=200 N=500
3 4
5
3 4 5 3 4 5
l
l
l
l
l l
l l l
0.
04
0.
08
0.
12
0.
16
RMSE
N=100 N=200 N=500
3 4 5
3
4 5
3 4 5
l l
l
l
l l
l
l l
0.
75
0.
85
0.
95
Coverage
N=100 N=200 N=500
3 4 5
3
4 5
3
4 5
(b) Correctly specified model without monotonicity
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(c) Misspecified model with monotonicity
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(d) Misspecified model without monotonicity
Fig. 7. Simulations for homogeneity (a) and (b) and heterogeneity (c) and (d). Each subgraph presents the
bias, RMSE, coverage proportions of the 95% credible intervals of ACEs¯s¯. Nine combinations of NR and N
are shown in (a) and (b); and nine combinations of N and d (“1” for .01, “2” for .025, “3” for .05) are shown in
(c) and (d).
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(a) Correctly specified model without monotonicity
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(b) Misspecified model without monotonicity
Fig. 8. Simulations for homogeneity (a) and (b) and heterogeneity (c) and (d). Each subgraph presents the
bias, RMSE, coverage proportions of the 95% credible intervals of ACEs¯s. Nine combinations of NR and N
are shown in (a) and (b); and nine combinations of N and d (“1” for .01, “2” for .025, “3” for .05) are shown in
(c) and (d).
